nodes	percent_of_prediction	percent_of_DWPC	metapath
Furosemide—SLC22A11—Conjugated Estrogens—prostate cancer	0.0723	0.136	CbGbCtD
Furosemide—SLC22A11—Estradiol—prostate cancer	0.0635	0.12	CbGbCtD
Furosemide—ABCC2—Ethinyl Estradiol—prostate cancer	0.0546	0.103	CbGbCtD
Furosemide—ALB—Abiraterone—prostate cancer	0.0528	0.0996	CbGbCtD
Furosemide—SLC22A8—Conjugated Estrogens—prostate cancer	0.0421	0.0794	CbGbCtD
Furosemide—ABCC2—Conjugated Estrogens—prostate cancer	0.04	0.0756	CbGbCtD
Furosemide—ALB—Estrone—prostate cancer	0.0381	0.072	CbGbCtD
Furosemide—SLC22A8—Estradiol—prostate cancer	0.0369	0.0697	CbGbCtD
Furosemide—SLC22A6—Conjugated Estrogens—prostate cancer	0.0293	0.0553	CbGbCtD
Furosemide—ABCC2—Etoposide—prostate cancer	0.023	0.0433	CbGbCtD
Furosemide—ALB—Estradiol—prostate cancer	0.0219	0.0413	CbGbCtD
Furosemide—ABCC2—Docetaxel—prostate cancer	0.021	0.0396	CbGbCtD
Furosemide—ALB—Prednisone—prostate cancer	0.0188	0.0355	CbGbCtD
Furosemide—ABCC2—Doxorubicin—prostate cancer	0.0157	0.0295	CbGbCtD
Furosemide—SLC12A1—urine—prostate cancer	0.00686	0.0854	CbGeAlD
Furosemide—SLC22A8—urine—prostate cancer	0.00398	0.0496	CbGeAlD
Furosemide—Bumetanide—SLC12A2—prostate cancer	0.00344	0.802	CrCbGaD
Furosemide—CA14—prostate gland—prostate cancer	0.00274	0.0341	CbGeAlD
Furosemide—SLC12A1—prostate gland—prostate cancer	0.00246	0.0306	CbGeAlD
Furosemide—CA14—seminal vesicle—prostate cancer	0.00232	0.0289	CbGeAlD
Furosemide—SLCO2A1—prostate gland—prostate cancer	0.00227	0.0283	CbGeAlD
Furosemide—CA7—renal system—prostate cancer	0.00225	0.0279	CbGeAlD
Furosemide—PGD—prostate gland—prostate cancer	0.00203	0.0252	CbGeAlD
Furosemide—SLCO2A1—seminal vesicle—prostate cancer	0.00192	0.0239	CbGeAlD
Furosemide—CA5B—prostate gland—prostate cancer	0.00192	0.0239	CbGeAlD
Furosemide—SLC12A1—epithelium—prostate cancer	0.00181	0.0225	CbGeAlD
Furosemide—SLC22A11—renal system—prostate cancer	0.00173	0.0215	CbGeAlD
Furosemide—PGD—seminal vesicle—prostate cancer	0.00171	0.0213	CbGeAlD
Furosemide—SLC12A1—renal system—prostate cancer	0.00168	0.0209	CbGeAlD
Furosemide—SLCO2A1—epithelium—prostate cancer	0.00167	0.0208	CbGeAlD
Furosemide—SLC12A1—urethra—prostate cancer	0.00165	0.0205	CbGeAlD
Furosemide—SLCO2A1—renal system—prostate cancer	0.00155	0.0193	CbGeAlD
Furosemide—SLCO2A1—urethra—prostate cancer	0.00152	0.0189	CbGeAlD
Furosemide—CA12—renal system—prostate cancer	0.00146	0.0181	CbGeAlD
Furosemide—SLC22A8—prostate gland—prostate cancer	0.00143	0.0178	CbGeAlD
Furosemide—ABCC2—prostate gland—prostate cancer	0.0014	0.0174	CbGeAlD
Furosemide—PGD—renal system—prostate cancer	0.00138	0.0172	CbGeAlD
Furosemide—PGD—urethra—prostate cancer	0.00136	0.0169	CbGeAlD
Furosemide—CA4—prostate gland—prostate cancer	0.00133	0.0165	CbGeAlD
Furosemide—CA5B—urethra—prostate cancer	0.00129	0.016	CbGeAlD
Furosemide—CA9—testis—prostate cancer	0.00127	0.0159	CbGeAlD
Furosemide—CA1—renal system—prostate cancer	0.00116	0.0144	CbGeAlD
Furosemide—CA4—seminal vesicle—prostate cancer	0.00112	0.0139	CbGeAlD
Furosemide—CA2—prostate gland—prostate cancer	0.0011	0.0137	CbGeAlD
Furosemide—SLC12A1—testis—prostate cancer	0.00109	0.0135	CbGeAlD
Furosemide—SLC22A5—prostate gland—prostate cancer	0.00108	0.0134	CbGeAlD
Furosemide—PGD—bone marrow—prostate cancer	0.00104	0.013	CbGeAlD
Furosemide—SLCO2A1—testis—prostate cancer	0.001	0.0125	CbGeAlD
Furosemide—SLC22A8—renal system—prostate cancer	0.000975	0.0121	CbGeAlD
Furosemide—ABCC2—renal system—prostate cancer	0.000951	0.0118	CbGeAlD
Furosemide—CA2—seminal vesicle—prostate cancer	0.00093	0.0116	CbGeAlD
Furosemide—SLC22A5—seminal vesicle—prostate cancer	0.000915	0.0114	CbGeAlD
Furosemide—CA4—renal system—prostate cancer	0.000903	0.0112	CbGeAlD
Furosemide—PGD—testis—prostate cancer	0.000893	0.0111	CbGeAlD
Furosemide—CA4—urethra—prostate cancer	0.000887	0.011	CbGeAlD
Furosemide—CA1—bone marrow—prostate cancer	0.000874	0.0109	CbGeAlD
Furosemide—CA5B—testis—prostate cancer	0.000846	0.0105	CbGeAlD
Furosemide—CA2—epithelium—prostate cancer	0.000808	0.01	CbGeAlD
Furosemide—CA2—renal system—prostate cancer	0.000749	0.00931	CbGeAlD
Furosemide—SLC22A5—renal system—prostate cancer	0.000737	0.00916	CbGeAlD
Furosemide—SLCO2A1—lymph node—prostate cancer	0.000726	0.00903	CbGeAlD
Furosemide—SLC22A5—urethra—prostate cancer	0.000724	0.009	CbGeAlD
Furosemide—CA4—bone marrow—prostate cancer	0.000683	0.00849	CbGeAlD
Furosemide—ALB—testis—prostate cancer	0.000656	0.00816	CbGeAlD
Furosemide—PGD—lymph node—prostate cancer	0.000647	0.00805	CbGeAlD
Furosemide—ABCC2—testis—prostate cancer	0.000615	0.00765	CbGeAlD
Furosemide—CA5B—lymph node—prostate cancer	0.000613	0.00762	CbGeAlD
Furosemide—CA4—testis—prostate cancer	0.000584	0.00726	CbGeAlD
Furosemide—CA2—bone marrow—prostate cancer	0.000566	0.00704	CbGeAlD
Furosemide—CA1—lymph node—prostate cancer	0.000541	0.00673	CbGeAlD
Furosemide—CA2—testis—prostate cancer	0.000484	0.00602	CbGeAlD
Furosemide—SLC22A5—testis—prostate cancer	0.000476	0.00592	CbGeAlD
Furosemide—ALB—lymph node—prostate cancer	0.000476	0.00591	CbGeAlD
Furosemide—Indapamide—CYP3A4—prostate cancer	0.000457	0.107	CrCbGaD
Furosemide—ABCC2—lymph node—prostate cancer	0.000446	0.00554	CbGeAlD
Furosemide—CA4—lymph node—prostate cancer	0.000423	0.00526	CbGeAlD
Furosemide—Bumetanide—PTGS2—prostate cancer	0.000394	0.0916	CrCbGaD
Furosemide—CA2—lymph node—prostate cancer	0.000351	0.00436	CbGeAlD
Furosemide—SLC22A5—lymph node—prostate cancer	0.000345	0.00429	CbGeAlD
Furosemide—Vertigo—Capecitabine—prostate cancer	8.33e-05	0.00032	CcSEcCtD
Furosemide—Hypersensitivity—Mitoxantrone—prostate cancer	8.33e-05	0.00032	CcSEcCtD
Furosemide—Diarrhoea—Estradiol—prostate cancer	8.3e-05	0.000319	CcSEcCtD
Furosemide—Leukopenia—Capecitabine—prostate cancer	8.3e-05	0.000319	CcSEcCtD
Furosemide—Drowsiness—Epirubicin—prostate cancer	8.26e-05	0.000317	CcSEcCtD
Furosemide—Erythema—Prednisone—prostate cancer	8.26e-05	0.000317	CcSEcCtD
Furosemide—Malnutrition—Prednisone—prostate cancer	8.26e-05	0.000317	CcSEcCtD
Furosemide—Stevens-Johnson syndrome—Epirubicin—prostate cancer	8.19e-05	0.000315	CcSEcCtD
Furosemide—Decreased appetite—Etoposide—prostate cancer	8.17e-05	0.000314	CcSEcCtD
Furosemide—Renal failure—Epirubicin—prostate cancer	8.12e-05	0.000312	CcSEcCtD
Furosemide—Gastrointestinal disorder—Etoposide—prostate cancer	8.12e-05	0.000312	CcSEcCtD
Furosemide—Asthenia—Mitoxantrone—prostate cancer	8.11e-05	0.000311	CcSEcCtD
Furosemide—Fatigue—Etoposide—prostate cancer	8.11e-05	0.000311	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	8.1e-05	0.000311	CcSEcCtD
Furosemide—Constipation—Etoposide—prostate cancer	8.04e-05	0.000309	CcSEcCtD
Furosemide—Pain—Etoposide—prostate cancer	8.04e-05	0.000309	CcSEcCtD
Furosemide—Dizziness—Estradiol—prostate cancer	8.02e-05	0.000308	CcSEcCtD
Furosemide—Dry mouth—Docetaxel—prostate cancer	7.97e-05	0.000306	CcSEcCtD
Furosemide—Sweating—Epirubicin—prostate cancer	7.92e-05	0.000304	CcSEcCtD
Furosemide—Pollakiuria—Doxorubicin—prostate cancer	7.92e-05	0.000304	CcSEcCtD
Furosemide—Confusional state—Docetaxel—prostate cancer	7.88e-05	0.000302	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	7.84e-05	0.000301	CcSEcCtD
Furosemide—Photosensitivity reaction—Doxorubicin—prostate cancer	7.83e-05	0.000301	CcSEcCtD
Furosemide—Hepatobiliary disease—Epirubicin—prostate cancer	7.82e-05	0.0003	CcSEcCtD
Furosemide—Anaphylactic shock—Docetaxel—prostate cancer	7.82e-05	0.0003	CcSEcCtD
Furosemide—Vision blurred—Prednisone—prostate cancer	7.78e-05	0.000299	CcSEcCtD
Furosemide—Feeling abnormal—Etoposide—prostate cancer	7.75e-05	0.000297	CcSEcCtD
Furosemide—Hyperglycaemia—Doxorubicin—prostate cancer	7.74e-05	0.000297	CcSEcCtD
Furosemide—Diarrhoea—Mitoxantrone—prostate cancer	7.74e-05	0.000297	CcSEcCtD
Furosemide—Dry mouth—Capecitabine—prostate cancer	7.72e-05	0.000296	CcSEcCtD
Furosemide—Vomiting—Estradiol—prostate cancer	7.71e-05	0.000296	CcSEcCtD
Furosemide—Agranulocytosis—Epirubicin—prostate cancer	7.71e-05	0.000296	CcSEcCtD
Furosemide—Gastrointestinal pain—Etoposide—prostate cancer	7.69e-05	0.000295	CcSEcCtD
Furosemide—Shock—Docetaxel—prostate cancer	7.69e-05	0.000295	CcSEcCtD
Furosemide—Nervous system disorder—Docetaxel—prostate cancer	7.66e-05	0.000294	CcSEcCtD
Furosemide—Thrombocytopenia—Docetaxel—prostate cancer	7.65e-05	0.000294	CcSEcCtD
Furosemide—Rash—Estradiol—prostate cancer	7.65e-05	0.000294	CcSEcCtD
Furosemide—Drowsiness—Doxorubicin—prostate cancer	7.65e-05	0.000294	CcSEcCtD
Furosemide—Dermatitis—Estradiol—prostate cancer	7.64e-05	0.000293	CcSEcCtD
Furosemide—Anaemia—Prednisone—prostate cancer	7.63e-05	0.000293	CcSEcCtD
Furosemide—Confusional state—Capecitabine—prostate cancer	7.63e-05	0.000293	CcSEcCtD
Furosemide—Headache—Estradiol—prostate cancer	7.6e-05	0.000292	CcSEcCtD
Furosemide—Skin disorder—Docetaxel—prostate cancer	7.59e-05	0.000291	CcSEcCtD
Furosemide—Agitation—Prednisone—prostate cancer	7.59e-05	0.000291	CcSEcCtD
Furosemide—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	7.58e-05	0.000291	CcSEcCtD
Furosemide—Renal failure—Doxorubicin—prostate cancer	7.52e-05	0.000289	CcSEcCtD
Furosemide—Urticaria—Etoposide—prostate cancer	7.47e-05	0.000287	CcSEcCtD
Furosemide—Anorexia—Docetaxel—prostate cancer	7.45e-05	0.000286	CcSEcCtD
Furosemide—Shock—Capecitabine—prostate cancer	7.44e-05	0.000286	CcSEcCtD
Furosemide—Abdominal pain—Etoposide—prostate cancer	7.43e-05	0.000285	CcSEcCtD
Furosemide—Body temperature increased—Etoposide—prostate cancer	7.43e-05	0.000285	CcSEcCtD
Furosemide—Nervous system disorder—Capecitabine—prostate cancer	7.42e-05	0.000285	CcSEcCtD
Furosemide—Vertigo—Prednisone—prostate cancer	7.42e-05	0.000285	CcSEcCtD
Furosemide—Thrombocytopenia—Capecitabine—prostate cancer	7.41e-05	0.000284	CcSEcCtD
Furosemide—Skin disorder—Capecitabine—prostate cancer	7.35e-05	0.000282	CcSEcCtD
Furosemide—Sweating—Doxorubicin—prostate cancer	7.33e-05	0.000281	CcSEcCtD
Furosemide—Urinary tract disorder—Epirubicin—prostate cancer	7.33e-05	0.000281	CcSEcCtD
Furosemide—Hyperhidrosis—Capecitabine—prostate cancer	7.31e-05	0.000281	CcSEcCtD
Furosemide—Hypotension—Docetaxel—prostate cancer	7.3e-05	0.00028	CcSEcCtD
Furosemide—Urethral disorder—Epirubicin—prostate cancer	7.27e-05	0.000279	CcSEcCtD
Furosemide—Hepatobiliary disease—Doxorubicin—prostate cancer	7.23e-05	0.000278	CcSEcCtD
Furosemide—Anorexia—Capecitabine—prostate cancer	7.21e-05	0.000277	CcSEcCtD
Furosemide—Nausea—Estradiol—prostate cancer	7.21e-05	0.000277	CcSEcCtD
Furosemide—Vomiting—Mitoxantrone—prostate cancer	7.19e-05	0.000276	CcSEcCtD
Furosemide—Visual impairment—Epirubicin—prostate cancer	7.15e-05	0.000274	CcSEcCtD
Furosemide—Agranulocytosis—Doxorubicin—prostate cancer	7.14e-05	0.000274	CcSEcCtD
Furosemide—Rash—Mitoxantrone—prostate cancer	7.13e-05	0.000274	CcSEcCtD
Furosemide—Dermatitis—Mitoxantrone—prostate cancer	7.12e-05	0.000273	CcSEcCtD
Furosemide—Headache—Mitoxantrone—prostate cancer	7.08e-05	0.000272	CcSEcCtD
Furosemide—Hypotension—Capecitabine—prostate cancer	7.07e-05	0.000271	CcSEcCtD
Furosemide—Paraesthesia—Docetaxel—prostate cancer	7.02e-05	0.000269	CcSEcCtD
Furosemide—Erythema multiforme—Epirubicin—prostate cancer	7.02e-05	0.000269	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	6.98e-05	0.000268	CcSEcCtD
Furosemide—Somnolence—Docetaxel—prostate cancer	6.95e-05	0.000267	CcSEcCtD
Furosemide—Eye disorder—Epirubicin—prostate cancer	6.93e-05	0.000266	CcSEcCtD
Furosemide—Hypersensitivity—Etoposide—prostate cancer	6.93e-05	0.000266	CcSEcCtD
Furosemide—Tinnitus—Epirubicin—prostate cancer	6.92e-05	0.000266	CcSEcCtD
Furosemide—Paraesthesia—Capecitabine—prostate cancer	6.79e-05	0.000261	CcSEcCtD
Furosemide—Decreased appetite—Docetaxel—prostate cancer	6.79e-05	0.000261	CcSEcCtD
Furosemide—Urinary tract disorder—Doxorubicin—prostate cancer	6.78e-05	0.00026	CcSEcCtD
Furosemide—Gastrointestinal disorder—Docetaxel—prostate cancer	6.75e-05	0.000259	CcSEcCtD
Furosemide—Asthenia—Etoposide—prostate cancer	6.75e-05	0.000259	CcSEcCtD
Furosemide—Anaphylactic shock—Prednisone—prostate cancer	6.74e-05	0.000259	CcSEcCtD
Furosemide—Fatigue—Docetaxel—prostate cancer	6.74e-05	0.000259	CcSEcCtD
Furosemide—Angiopathy—Epirubicin—prostate cancer	6.73e-05	0.000258	CcSEcCtD
Furosemide—Urethral disorder—Doxorubicin—prostate cancer	6.73e-05	0.000258	CcSEcCtD
Furosemide—Nausea—Mitoxantrone—prostate cancer	6.72e-05	0.000258	CcSEcCtD
Furosemide—Immune system disorder—Epirubicin—prostate cancer	6.7e-05	0.000257	CcSEcCtD
Furosemide—Constipation—Docetaxel—prostate cancer	6.68e-05	0.000257	CcSEcCtD
Furosemide—Pain—Docetaxel—prostate cancer	6.68e-05	0.000257	CcSEcCtD
Furosemide—Pruritus—Etoposide—prostate cancer	6.65e-05	0.000255	CcSEcCtD
Furosemide—Shock—Prednisone—prostate cancer	6.63e-05	0.000255	CcSEcCtD
Furosemide—Arrhythmia—Epirubicin—prostate cancer	6.63e-05	0.000254	CcSEcCtD
Furosemide—Visual impairment—Doxorubicin—prostate cancer	6.62e-05	0.000254	CcSEcCtD
Furosemide—Nervous system disorder—Prednisone—prostate cancer	6.61e-05	0.000254	CcSEcCtD
Furosemide—Decreased appetite—Capecitabine—prostate cancer	6.58e-05	0.000252	CcSEcCtD
Furosemide—Skin disorder—Prednisone—prostate cancer	6.55e-05	0.000251	CcSEcCtD
Furosemide—Gastrointestinal disorder—Capecitabine—prostate cancer	6.53e-05	0.000251	CcSEcCtD
Furosemide—Fatigue—Capecitabine—prostate cancer	6.52e-05	0.00025	CcSEcCtD
Furosemide—Hyperhidrosis—Prednisone—prostate cancer	6.52e-05	0.00025	CcSEcCtD
Furosemide—Erythema multiforme—Doxorubicin—prostate cancer	6.49e-05	0.000249	CcSEcCtD
Furosemide—Pain—Capecitabine—prostate cancer	6.47e-05	0.000248	CcSEcCtD
Furosemide—Constipation—Capecitabine—prostate cancer	6.47e-05	0.000248	CcSEcCtD
Furosemide—Malnutrition—Epirubicin—prostate cancer	6.46e-05	0.000248	CcSEcCtD
Furosemide—Erythema—Epirubicin—prostate cancer	6.46e-05	0.000248	CcSEcCtD
Furosemide—Feeling abnormal—Docetaxel—prostate cancer	6.44e-05	0.000247	CcSEcCtD
Furosemide—Diarrhoea—Etoposide—prostate cancer	6.43e-05	0.000247	CcSEcCtD
Furosemide—Anorexia—Prednisone—prostate cancer	6.42e-05	0.000247	CcSEcCtD
Furosemide—Eye disorder—Doxorubicin—prostate cancer	6.42e-05	0.000246	CcSEcCtD
Furosemide—Tinnitus—Doxorubicin—prostate cancer	6.4e-05	0.000246	CcSEcCtD
Furosemide—Gastrointestinal pain—Docetaxel—prostate cancer	6.39e-05	0.000245	CcSEcCtD
Furosemide—Flatulence—Epirubicin—prostate cancer	6.36e-05	0.000244	CcSEcCtD
Furosemide—Dysgeusia—Epirubicin—prostate cancer	6.32e-05	0.000243	CcSEcCtD
Furosemide—Feeling abnormal—Capecitabine—prostate cancer	6.24e-05	0.000239	CcSEcCtD
Furosemide—Angiopathy—Doxorubicin—prostate cancer	6.23e-05	0.000239	CcSEcCtD
Furosemide—Dizziness—Etoposide—prostate cancer	6.22e-05	0.000239	CcSEcCtD
Furosemide—Muscle spasms—Epirubicin—prostate cancer	6.21e-05	0.000238	CcSEcCtD
Furosemide—Immune system disorder—Doxorubicin—prostate cancer	6.2e-05	0.000238	CcSEcCtD
Furosemide—Gastrointestinal pain—Capecitabine—prostate cancer	6.19e-05	0.000238	CcSEcCtD
Furosemide—Abdominal pain—Docetaxel—prostate cancer	6.18e-05	0.000237	CcSEcCtD
Furosemide—Body temperature increased—Docetaxel—prostate cancer	6.18e-05	0.000237	CcSEcCtD
Furosemide—Arrhythmia—Doxorubicin—prostate cancer	6.13e-05	0.000235	CcSEcCtD
Furosemide—Vision blurred—Epirubicin—prostate cancer	6.09e-05	0.000234	CcSEcCtD
Furosemide—Paraesthesia—Prednisone—prostate cancer	6.05e-05	0.000232	CcSEcCtD
Furosemide—Urticaria—Capecitabine—prostate cancer	6.01e-05	0.000231	CcSEcCtD
Furosemide—Abdominal pain—Capecitabine—prostate cancer	5.98e-05	0.00023	CcSEcCtD
Furosemide—Body temperature increased—Capecitabine—prostate cancer	5.98e-05	0.00023	CcSEcCtD
Furosemide—Vomiting—Etoposide—prostate cancer	5.98e-05	0.00023	CcSEcCtD
Furosemide—Erythema—Doxorubicin—prostate cancer	5.98e-05	0.000229	CcSEcCtD
Furosemide—Malnutrition—Doxorubicin—prostate cancer	5.98e-05	0.000229	CcSEcCtD
Furosemide—Anaemia—Epirubicin—prostate cancer	5.97e-05	0.000229	CcSEcCtD
Furosemide—Agitation—Epirubicin—prostate cancer	5.94e-05	0.000228	CcSEcCtD
Furosemide—Rash—Etoposide—prostate cancer	5.93e-05	0.000228	CcSEcCtD
Furosemide—Dermatitis—Etoposide—prostate cancer	5.92e-05	0.000227	CcSEcCtD
Furosemide—Headache—Etoposide—prostate cancer	5.89e-05	0.000226	CcSEcCtD
Furosemide—Flatulence—Doxorubicin—prostate cancer	5.89e-05	0.000226	CcSEcCtD
Furosemide—Decreased appetite—Prednisone—prostate cancer	5.86e-05	0.000225	CcSEcCtD
Furosemide—Dysgeusia—Doxorubicin—prostate cancer	5.85e-05	0.000225	CcSEcCtD
Furosemide—Fatigue—Prednisone—prostate cancer	5.81e-05	0.000223	CcSEcCtD
Furosemide—Vertigo—Epirubicin—prostate cancer	5.8e-05	0.000223	CcSEcCtD
Furosemide—Leukopenia—Epirubicin—prostate cancer	5.78e-05	0.000222	CcSEcCtD
Furosemide—Constipation—Prednisone—prostate cancer	5.76e-05	0.000221	CcSEcCtD
Furosemide—Hypersensitivity—Docetaxel—prostate cancer	5.76e-05	0.000221	CcSEcCtD
Furosemide—Muscle spasms—Doxorubicin—prostate cancer	5.75e-05	0.000221	CcSEcCtD
Furosemide—Vision blurred—Doxorubicin—prostate cancer	5.63e-05	0.000216	CcSEcCtD
Furosemide—Asthenia—Docetaxel—prostate cancer	5.61e-05	0.000215	CcSEcCtD
Furosemide—Nausea—Etoposide—prostate cancer	5.59e-05	0.000214	CcSEcCtD
Furosemide—Hypersensitivity—Capecitabine—prostate cancer	5.57e-05	0.000214	CcSEcCtD
Furosemide—Feeling abnormal—Prednisone—prostate cancer	5.55e-05	0.000213	CcSEcCtD
Furosemide—Pruritus—Docetaxel—prostate cancer	5.53e-05	0.000212	CcSEcCtD
Furosemide—Anaemia—Doxorubicin—prostate cancer	5.52e-05	0.000212	CcSEcCtD
Furosemide—Gastrointestinal pain—Prednisone—prostate cancer	5.51e-05	0.000212	CcSEcCtD
Furosemide—Agitation—Doxorubicin—prostate cancer	5.49e-05	0.000211	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.46e-05	0.00021	CcSEcCtD
Furosemide—Asthenia—Capecitabine—prostate cancer	5.43e-05	0.000208	CcSEcCtD
Furosemide—Dry mouth—Epirubicin—prostate cancer	5.38e-05	0.000206	CcSEcCtD
Furosemide—Vertigo—Doxorubicin—prostate cancer	5.37e-05	0.000206	CcSEcCtD
Furosemide—Urticaria—Prednisone—prostate cancer	5.35e-05	0.000206	CcSEcCtD
Furosemide—Pruritus—Capecitabine—prostate cancer	5.35e-05	0.000205	CcSEcCtD
Furosemide—Leukopenia—Doxorubicin—prostate cancer	5.35e-05	0.000205	CcSEcCtD
Furosemide—Diarrhoea—Docetaxel—prostate cancer	5.35e-05	0.000205	CcSEcCtD
Furosemide—Abdominal pain—Prednisone—prostate cancer	5.33e-05	0.000205	CcSEcCtD
Furosemide—Body temperature increased—Prednisone—prostate cancer	5.33e-05	0.000205	CcSEcCtD
Furosemide—Confusional state—Epirubicin—prostate cancer	5.32e-05	0.000204	CcSEcCtD
Furosemide—Anaphylactic shock—Epirubicin—prostate cancer	5.27e-05	0.000202	CcSEcCtD
Furosemide—Shock—Epirubicin—prostate cancer	5.19e-05	0.000199	CcSEcCtD
Furosemide—Diarrhoea—Capecitabine—prostate cancer	5.18e-05	0.000199	CcSEcCtD
Furosemide—Nervous system disorder—Epirubicin—prostate cancer	5.17e-05	0.000198	CcSEcCtD
Furosemide—Dizziness—Docetaxel—prostate cancer	5.17e-05	0.000198	CcSEcCtD
Furosemide—Thrombocytopenia—Epirubicin—prostate cancer	5.16e-05	0.000198	CcSEcCtD
Furosemide—Skin disorder—Epirubicin—prostate cancer	5.12e-05	0.000197	CcSEcCtD
Furosemide—Hyperhidrosis—Epirubicin—prostate cancer	5.1e-05	0.000196	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.05e-05	0.000194	CcSEcCtD
Furosemide—Anorexia—Epirubicin—prostate cancer	5.02e-05	0.000193	CcSEcCtD
Furosemide—Dizziness—Capecitabine—prostate cancer	5e-05	0.000192	CcSEcCtD
Furosemide—Dry mouth—Doxorubicin—prostate cancer	4.98e-05	0.000191	CcSEcCtD
Furosemide—Vomiting—Docetaxel—prostate cancer	4.97e-05	0.000191	CcSEcCtD
Furosemide—Hypersensitivity—Prednisone—prostate cancer	4.97e-05	0.000191	CcSEcCtD
Furosemide—Rash—Docetaxel—prostate cancer	4.93e-05	0.000189	CcSEcCtD
Furosemide—Hypotension—Epirubicin—prostate cancer	4.93e-05	0.000189	CcSEcCtD
Furosemide—Dermatitis—Docetaxel—prostate cancer	4.92e-05	0.000189	CcSEcCtD
Furosemide—Confusional state—Doxorubicin—prostate cancer	4.92e-05	0.000189	CcSEcCtD
Furosemide—Headache—Docetaxel—prostate cancer	4.9e-05	0.000188	CcSEcCtD
Furosemide—Anaphylactic shock—Doxorubicin—prostate cancer	4.88e-05	0.000187	CcSEcCtD
Furosemide—Asthenia—Prednisone—prostate cancer	4.84e-05	0.000186	CcSEcCtD
Furosemide—Vomiting—Capecitabine—prostate cancer	4.81e-05	0.000185	CcSEcCtD
Furosemide—Shock—Doxorubicin—prostate cancer	4.8e-05	0.000184	CcSEcCtD
Furosemide—Nervous system disorder—Doxorubicin—prostate cancer	4.78e-05	0.000184	CcSEcCtD
Furosemide—Thrombocytopenia—Doxorubicin—prostate cancer	4.78e-05	0.000183	CcSEcCtD
Furosemide—Rash—Capecitabine—prostate cancer	4.77e-05	0.000183	CcSEcCtD
Furosemide—Pruritus—Prednisone—prostate cancer	4.77e-05	0.000183	CcSEcCtD
Furosemide—Dermatitis—Capecitabine—prostate cancer	4.77e-05	0.000183	CcSEcCtD
Furosemide—Headache—Capecitabine—prostate cancer	4.74e-05	0.000182	CcSEcCtD
Furosemide—Skin disorder—Doxorubicin—prostate cancer	4.74e-05	0.000182	CcSEcCtD
Furosemide—Paraesthesia—Epirubicin—prostate cancer	4.73e-05	0.000182	CcSEcCtD
Furosemide—Hyperhidrosis—Doxorubicin—prostate cancer	4.72e-05	0.000181	CcSEcCtD
Furosemide—Somnolence—Epirubicin—prostate cancer	4.69e-05	0.00018	CcSEcCtD
Furosemide—Anorexia—Doxorubicin—prostate cancer	4.65e-05	0.000178	CcSEcCtD
Furosemide—Nausea—Docetaxel—prostate cancer	4.64e-05	0.000178	CcSEcCtD
Furosemide—Diarrhoea—Prednisone—prostate cancer	4.61e-05	0.000177	CcSEcCtD
Furosemide—Decreased appetite—Epirubicin—prostate cancer	4.58e-05	0.000176	CcSEcCtD
Furosemide—Hypotension—Doxorubicin—prostate cancer	4.56e-05	0.000175	CcSEcCtD
Furosemide—Gastrointestinal disorder—Epirubicin—prostate cancer	4.55e-05	0.000175	CcSEcCtD
Furosemide—Fatigue—Epirubicin—prostate cancer	4.54e-05	0.000174	CcSEcCtD
Furosemide—Constipation—Epirubicin—prostate cancer	4.51e-05	0.000173	CcSEcCtD
Furosemide—Pain—Epirubicin—prostate cancer	4.51e-05	0.000173	CcSEcCtD
Furosemide—Nausea—Capecitabine—prostate cancer	4.49e-05	0.000173	CcSEcCtD
Furosemide—Dizziness—Prednisone—prostate cancer	4.46e-05	0.000171	CcSEcCtD
Furosemide—Paraesthesia—Doxorubicin—prostate cancer	4.38e-05	0.000168	CcSEcCtD
Furosemide—Feeling abnormal—Epirubicin—prostate cancer	4.34e-05	0.000167	CcSEcCtD
Furosemide—Somnolence—Doxorubicin—prostate cancer	4.34e-05	0.000166	CcSEcCtD
Furosemide—Gastrointestinal pain—Epirubicin—prostate cancer	4.31e-05	0.000165	CcSEcCtD
Furosemide—Vomiting—Prednisone—prostate cancer	4.29e-05	0.000164	CcSEcCtD
Furosemide—Rash—Prednisone—prostate cancer	4.25e-05	0.000163	CcSEcCtD
Furosemide—Dermatitis—Prednisone—prostate cancer	4.25e-05	0.000163	CcSEcCtD
Furosemide—Decreased appetite—Doxorubicin—prostate cancer	4.24e-05	0.000163	CcSEcCtD
Furosemide—Headache—Prednisone—prostate cancer	4.22e-05	0.000162	CcSEcCtD
Furosemide—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.21e-05	0.000162	CcSEcCtD
Furosemide—Fatigue—Doxorubicin—prostate cancer	4.21e-05	0.000161	CcSEcCtD
Furosemide—Urticaria—Epirubicin—prostate cancer	4.19e-05	0.000161	CcSEcCtD
Furosemide—Pain—Doxorubicin—prostate cancer	4.17e-05	0.00016	CcSEcCtD
Furosemide—Constipation—Doxorubicin—prostate cancer	4.17e-05	0.00016	CcSEcCtD
Furosemide—Abdominal pain—Epirubicin—prostate cancer	4.17e-05	0.00016	CcSEcCtD
Furosemide—Body temperature increased—Epirubicin—prostate cancer	4.17e-05	0.00016	CcSEcCtD
Furosemide—Feeling abnormal—Doxorubicin—prostate cancer	4.02e-05	0.000154	CcSEcCtD
Furosemide—Nausea—Prednisone—prostate cancer	4e-05	0.000154	CcSEcCtD
Furosemide—Gastrointestinal pain—Doxorubicin—prostate cancer	3.99e-05	0.000153	CcSEcCtD
Furosemide—Hypersensitivity—Epirubicin—prostate cancer	3.88e-05	0.000149	CcSEcCtD
Furosemide—Urticaria—Doxorubicin—prostate cancer	3.87e-05	0.000149	CcSEcCtD
Furosemide—Abdominal pain—Doxorubicin—prostate cancer	3.86e-05	0.000148	CcSEcCtD
Furosemide—Body temperature increased—Doxorubicin—prostate cancer	3.86e-05	0.000148	CcSEcCtD
Furosemide—Asthenia—Epirubicin—prostate cancer	3.78e-05	0.000145	CcSEcCtD
Furosemide—Pruritus—Epirubicin—prostate cancer	3.73e-05	0.000143	CcSEcCtD
Furosemide—Diarrhoea—Epirubicin—prostate cancer	3.61e-05	0.000138	CcSEcCtD
Furosemide—Hypersensitivity—Doxorubicin—prostate cancer	3.59e-05	0.000138	CcSEcCtD
Furosemide—Asthenia—Doxorubicin—prostate cancer	3.5e-05	0.000134	CcSEcCtD
Furosemide—Dizziness—Epirubicin—prostate cancer	3.49e-05	0.000134	CcSEcCtD
Furosemide—Pruritus—Doxorubicin—prostate cancer	3.45e-05	0.000132	CcSEcCtD
Furosemide—Vomiting—Epirubicin—prostate cancer	3.35e-05	0.000129	CcSEcCtD
Furosemide—Diarrhoea—Doxorubicin—prostate cancer	3.34e-05	0.000128	CcSEcCtD
Furosemide—Rash—Epirubicin—prostate cancer	3.32e-05	0.000128	CcSEcCtD
Furosemide—Dermatitis—Epirubicin—prostate cancer	3.32e-05	0.000127	CcSEcCtD
Furosemide—Headache—Epirubicin—prostate cancer	3.3e-05	0.000127	CcSEcCtD
Furosemide—Dizziness—Doxorubicin—prostate cancer	3.23e-05	0.000124	CcSEcCtD
Furosemide—Nausea—Epirubicin—prostate cancer	3.13e-05	0.00012	CcSEcCtD
Furosemide—Vomiting—Doxorubicin—prostate cancer	3.1e-05	0.000119	CcSEcCtD
Furosemide—Rash—Doxorubicin—prostate cancer	3.08e-05	0.000118	CcSEcCtD
Furosemide—Dermatitis—Doxorubicin—prostate cancer	3.07e-05	0.000118	CcSEcCtD
Furosemide—Headache—Doxorubicin—prostate cancer	3.06e-05	0.000117	CcSEcCtD
Furosemide—Nausea—Doxorubicin—prostate cancer	2.9e-05	0.000111	CcSEcCtD
Furosemide—ALB—Platelet activation, signaling and aggregation—IGF1—prostate cancer	1.33e-05	0.000106	CbGpPWpGaD
Furosemide—CA12—Metabolism—PIK3CD—prostate cancer	1.33e-05	0.000106	CbGpPWpGaD
Furosemide—CA9—Metabolism—TYMS—prostate cancer	1.32e-05	0.000106	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PTGS2—prostate cancer	1.32e-05	0.000106	CbGpPWpGaD
Furosemide—CA6—Metabolism—PTGS2—prostate cancer	1.32e-05	0.000106	CbGpPWpGaD
Furosemide—CA4—Metabolism—CAV1—prostate cancer	1.32e-05	0.000106	CbGpPWpGaD
Furosemide—CA1—Metabolism—MTHFR—prostate cancer	1.32e-05	0.000105	CbGpPWpGaD
Furosemide—CA9—Metabolism—GSTM1—prostate cancer	1.31e-05	0.000105	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—PRKACB—prostate cancer	1.31e-05	0.000105	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	1.3e-05	0.000104	CbGpPWpGaD
Furosemide—CA1—Metabolism—PPARA—prostate cancer	1.29e-05	0.000103	CbGpPWpGaD
Furosemide—PGD—Metabolism—PIK3CB—prostate cancer	1.29e-05	0.000103	CbGpPWpGaD
Furosemide—CA9—Metabolism—LPL—prostate cancer	1.29e-05	0.000103	CbGpPWpGaD
Furosemide—ALB—Metabolism—HPGD—prostate cancer	1.28e-05	0.000103	CbGpPWpGaD
Furosemide—ALB—Metabolism—B4GALT4—prostate cancer	1.28e-05	0.000103	CbGpPWpGaD
Furosemide—PGD—Metabolism—PTGS2—prostate cancer	1.28e-05	0.000102	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—PIK3CD—prostate cancer	1.28e-05	0.000102	CbGpPWpGaD
Furosemide—PGD—Disease—EP300—prostate cancer	1.27e-05	0.000102	CbGpPWpGaD
Furosemide—CA2—Metabolism—CAV1—prostate cancer	1.27e-05	0.000101	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—SERPINE1—prostate cancer	1.26e-05	0.000101	CbGpPWpGaD
Furosemide—ALB—Selenium Micronutrient Network—IL6—prostate cancer	1.25e-05	0.0001	CbGpPWpGaD
Furosemide—CA12—Metabolism—NOS3—prostate cancer	1.25e-05	0.0001	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PIK3CB—prostate cancer	1.25e-05	0.0001	CbGpPWpGaD
Furosemide—CA7—Metabolism—PIK3CB—prostate cancer	1.25e-05	0.0001	CbGpPWpGaD
Furosemide—CA9—Metabolism—CYP1A1—prostate cancer	1.24e-05	9.94e-05	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PTGS2—prostate cancer	1.24e-05	9.9e-05	CbGpPWpGaD
Furosemide—CA7—Metabolism—PTGS2—prostate cancer	1.24e-05	9.9e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—NCOA2—prostate cancer	1.23e-05	9.89e-05	CbGpPWpGaD
Furosemide—PGD—Disease—SRC—prostate cancer	1.23e-05	9.88e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—ERCC2—prostate cancer	1.23e-05	9.86e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—CAV1—prostate cancer	1.21e-05	9.73e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PRKCQ—prostate cancer	1.21e-05	9.71e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—TNFRSF21—prostate cancer	1.21e-05	9.66e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—PIK3CG—prostate cancer	1.2e-05	9.64e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PLAUR—prostate cancer	1.2e-05	9.6e-05	CbGpPWpGaD
Furosemide—PGD—Disease—STAT3—prostate cancer	1.19e-05	9.53e-05	CbGpPWpGaD
Furosemide—CA14—Metabolism—PTEN—prostate cancer	1.19e-05	9.49e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—SLC5A5—prostate cancer	1.18e-05	9.43e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP7B1—prostate cancer	1.17e-05	9.4e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—MTAP—prostate cancer	1.17e-05	9.4e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—JAK2—prostate cancer	1.17e-05	9.38e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—MTHFR—prostate cancer	1.16e-05	9.27e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—PIK3CB—prostate cancer	1.16e-05	9.26e-05	CbGpPWpGaD
Furosemide—CA6—Metabolism—PTEN—prostate cancer	1.15e-05	9.25e-05	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PTEN—prostate cancer	1.15e-05	9.25e-05	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.15e-05	9.25e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—PIK3CG—prostate cancer	1.15e-05	9.24e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	1.15e-05	9.19e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—PTGS2—prostate cancer	1.15e-05	9.18e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—SULT1E1—prostate cancer	1.14e-05	9.16e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—SRD5A1—prostate cancer	1.14e-05	9.16e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—INS—prostate cancer	1.14e-05	9.12e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PPARA—prostate cancer	1.14e-05	9.09e-05	CbGpPWpGaD
Furosemide—CA14—Metabolism—EP300—prostate cancer	1.13e-05	9.05e-05	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.12e-05	8.96e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—CREBBP—prostate cancer	1.12e-05	8.94e-05	CbGpPWpGaD
Furosemide—PGD—Metabolism—PTEN—prostate cancer	1.11e-05	8.93e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—VAV3—prostate cancer	1.11e-05	8.91e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—PIK3CB—prostate cancer	1.11e-05	8.9e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	1.11e-05	8.9e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—PIK3CG—prostate cancer	1.11e-05	8.86e-05	CbGpPWpGaD
Furosemide—PGD—Disease—MYC—prostate cancer	1.11e-05	8.86e-05	CbGpPWpGaD
Furosemide—PGD—Disease—TGFB1—prostate cancer	1.1e-05	8.84e-05	CbGpPWpGaD
Furosemide—CA5A—Metabolism—EP300—prostate cancer	1.1e-05	8.82e-05	CbGpPWpGaD
Furosemide—CA6—Metabolism—EP300—prostate cancer	1.1e-05	8.82e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	1.09e-05	8.76e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—INS—prostate cancer	1.09e-05	8.75e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ACSL4—prostate cancer	1.09e-05	8.74e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—HSD17B3—prostate cancer	1.09e-05	8.74e-05	CbGpPWpGaD
Furosemide—PGD—Disease—EGFR—prostate cancer	1.08e-05	8.66e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—ITPR1—prostate cancer	1.08e-05	8.64e-05	CbGpPWpGaD
Furosemide—CA7—Metabolism—PTEN—prostate cancer	1.08e-05	8.64e-05	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PTEN—prostate cancer	1.08e-05	8.64e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	1.08e-05	8.64e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—CREBBP—prostate cancer	1.07e-05	8.57e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—CAV1—prostate cancer	1.07e-05	8.55e-05	CbGpPWpGaD
Furosemide—PGD—Metabolism—EP300—prostate cancer	1.06e-05	8.51e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—PIK3CD—prostate cancer	1.06e-05	8.47e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—INS—prostate cancer	1.05e-05	8.39e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PHGDH—prostate cancer	1.05e-05	8.38e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—UMPS—prostate cancer	1.05e-05	8.38e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ARG2—prostate cancer	1.05e-05	8.38e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	1.04e-05	8.34e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—NCOA1—prostate cancer	1.04e-05	8.33e-05	CbGpPWpGaD
Furosemide—CA7—Metabolism—EP300—prostate cancer	1.03e-05	8.24e-05	CbGpPWpGaD
Furosemide—CA5B—Metabolism—EP300—prostate cancer	1.03e-05	8.24e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—LDHB—prostate cancer	1.03e-05	8.22e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—CREBBP—prostate cancer	1.03e-05	8.21e-05	CbGpPWpGaD
Furosemide—PGD—Disease—KRAS—prostate cancer	1.02e-05	8.18e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—IL2—prostate cancer	1.02e-05	8.18e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—PIK3CD—prostate cancer	1.01e-05	8.12e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP3A5—prostate cancer	1.01e-05	8.06e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—PTEN—prostate cancer	9.99e-06	8e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—NOS3—prostate cancer	9.99e-06	8e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—RXRA—prostate cancer	9.89e-06	7.93e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PDHA1—prostate cancer	9.72e-06	7.79e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTA3—prostate cancer	9.72e-06	7.79e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—TCN2—prostate cancer	9.72e-06	7.79e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—UCP3—prostate cancer	9.72e-06	7.79e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PIK3CG—prostate cancer	9.72e-06	7.79e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—PIK3CD—prostate cancer	9.72e-06	7.79e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—NOS3—prostate cancer	9.57e-06	7.67e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—ITGB3—prostate cancer	9.55e-06	7.65e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—EP300—prostate cancer	9.53e-06	7.63e-05	CbGpPWpGaD
Furosemide—PGD—Disease—PIK3CA—prostate cancer	9.39e-06	7.52e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—HSD3B1—prostate cancer	9.27e-06	7.43e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—SLC22A3—prostate cancer	9.27e-06	7.43e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—PIK3CB—prostate cancer	9.22e-06	7.38e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—INS—prostate cancer	9.2e-06	7.37e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—NOS3—prostate cancer	9.18e-06	7.35e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—PTGS2—prostate cancer	9.13e-06	7.32e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—CREBBP—prostate cancer	9.01e-06	7.22e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—LPL—prostate cancer	9e-06	7.21e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—SRC—prostate cancer	8.91e-06	7.14e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—TBXAS1—prostate cancer	8.89e-06	7.12e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTA4—prostate cancer	8.89e-06	7.12e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—PIK3CB—prostate cancer	8.84e-06	7.08e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—PTGS2—prostate cancer	8.76e-06	7.02e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	8.69e-06	6.96e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—VEGFA—prostate cancer	8.67e-06	6.95e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTA2—prostate cancer	8.66e-06	6.94e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ABCG5—prostate cancer	8.56e-06	6.86e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—SULT1A1—prostate cancer	8.56e-06	6.86e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PIK3CD—prostate cancer	8.55e-06	6.85e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—PIK3CB—prostate cancer	8.47e-06	6.79e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PLAU—prostate cancer	8.4e-06	6.73e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—PTGS2—prostate cancer	8.4e-06	6.73e-05	CbGpPWpGaD
Furosemide—CA14—Metabolism—PIK3CA—prostate cancer	8.36e-06	6.7e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTA1—prostate cancer	8.36e-06	6.7e-05	CbGpPWpGaD
Furosemide—PGD—Disease—IL6—prostate cancer	8.31e-06	6.66e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—HSD3B2—prostate cancer	8.27e-06	6.62e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NAT2—prostate cancer	8.27e-06	6.62e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTO1—prostate cancer	8.27e-06	6.62e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—CAV1—prostate cancer	8.21e-06	6.58e-05	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PIK3CA—prostate cancer	8.15e-06	6.53e-05	CbGpPWpGaD
Furosemide—CA6—Metabolism—PIK3CA—prostate cancer	8.15e-06	6.53e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—NOS3—prostate cancer	8.07e-06	6.46e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—PTEN—prostate cancer	7.97e-06	6.38e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—TGFB1—prostate cancer	7.96e-06	6.38e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	7.95e-06	6.37e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—LRP2—prostate cancer	7.92e-06	6.35e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PLCB2—prostate cancer	7.92e-06	6.35e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP2C18—prostate cancer	7.92e-06	6.35e-05	CbGpPWpGaD
Furosemide—PGD—Metabolism—PIK3CA—prostate cancer	7.86e-06	6.3e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—P4HB—prostate cancer	7.77e-06	6.23e-05	CbGpPWpGaD
Furosemide—PGD—Disease—AKT1—prostate cancer	7.67e-06	6.14e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—PTEN—prostate cancer	7.64e-06	6.12e-05	CbGpPWpGaD
Furosemide—CA7—Metabolism—PIK3CA—prostate cancer	7.61e-06	6.09e-05	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PIK3CA—prostate cancer	7.61e-06	6.09e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—EP300—prostate cancer	7.6e-06	6.09e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—SLC22A1—prostate cancer	7.56e-06	6.06e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—PPARA—prostate cancer	7.56e-06	6.05e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PIK3CG—prostate cancer	7.48e-06	5.99e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	7.47e-06	5.99e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PIK3CB—prostate cancer	7.45e-06	5.97e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—EGF—prostate cancer	7.39e-06	5.92e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PTGS2—prostate cancer	7.38e-06	5.91e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—SULT2A1—prostate cancer	7.37e-06	5.9e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—PTEN—prostate cancer	7.32e-06	5.87e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—EP300—prostate cancer	7.28e-06	5.83e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—MED12—prostate cancer	7.25e-06	5.81e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GNG5—prostate cancer	7.19e-06	5.76e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—PIK3CA—prostate cancer	7.05e-06	5.65e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—EP300—prostate cancer	6.98e-06	5.59e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—CREBBP—prostate cancer	6.93e-06	5.55e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NCOA3—prostate cancer	6.93e-06	5.55e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—IGF1—prostate cancer	6.85e-06	5.48e-05	CbGpPWpGaD
Furosemide—CA14—Metabolism—AKT1—prostate cancer	6.83e-06	5.47e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	6.81e-06	5.45e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—PIK3CA—prostate cancer	6.78e-06	5.43e-05	CbGpPWpGaD
Furosemide—CA5A—Metabolism—AKT1—prostate cancer	6.66e-06	5.33e-05	CbGpPWpGaD
Furosemide—CA6—Metabolism—AKT1—prostate cancer	6.66e-06	5.33e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—HPGDS—prostate cancer	6.61e-06	5.29e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PIK3CD—prostate cancer	6.57e-06	5.27e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP2C19—prostate cancer	6.57e-06	5.26e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—SERPINE1—prostate cancer	6.5e-06	5.21e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PTEN—prostate cancer	6.44e-06	5.16e-05	CbGpPWpGaD
Furosemide—PGD—Metabolism—AKT1—prostate cancer	6.42e-06	5.14e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ACHE—prostate cancer	6.41e-06	5.13e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTT1—prostate cancer	6.41e-06	5.13e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP2A6—prostate cancer	6.34e-06	5.08e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	6.31e-06	5.06e-05	CbGpPWpGaD
Furosemide—CA5B—Metabolism—AKT1—prostate cancer	6.21e-06	4.98e-05	CbGpPWpGaD
Furosemide—CA7—Metabolism—AKT1—prostate cancer	6.21e-06	4.98e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—NOS3—prostate cancer	6.21e-06	4.97e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—AKR1C3—prostate cancer	6.16e-06	4.94e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—EP300—prostate cancer	6.14e-06	4.92e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PRKACB—prostate cancer	6.13e-06	4.91e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP17A1—prostate cancer	6.07e-06	4.86e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—JAK2—prostate cancer	6.03e-06	4.83e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—CREBBP—prostate cancer	6e-06	4.81e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	5.98e-06	4.79e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NCOA2—prostate cancer	5.78e-06	4.63e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—AKT1—prostate cancer	5.76e-06	4.61e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PIK3CB—prostate cancer	5.73e-06	4.59e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—PIK3CA—prostate cancer	5.62e-06	4.5e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—AKT1—prostate cancer	5.54e-06	4.43e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—SLC5A5—prostate cancer	5.52e-06	4.42e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—PIK3CA—prostate cancer	5.39e-06	4.32e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP2E1—prostate cancer	5.39e-06	4.32e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NQO1—prostate cancer	5.33e-06	4.27e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—IL2—prostate cancer	5.26e-06	4.22e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—TH—prostate cancer	5.25e-06	4.21e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	5.22e-06	4.18e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP3A4—prostate cancer	5.19e-06	4.16e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	5.17e-06	4.14e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—PIK3CA—prostate cancer	5.17e-06	4.14e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP1B1—prostate cancer	5.11e-06	4.09e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GGT1—prostate cancer	4.95e-06	3.96e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NCOA1—prostate cancer	4.87e-06	3.9e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP19A1—prostate cancer	4.8e-06	3.85e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—EP300—prostate cancer	4.72e-06	3.78e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—RXRA—prostate cancer	4.63e-06	3.71e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—SRC—prostate cancer	4.59e-06	3.68e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—AKT1—prostate cancer	4.59e-06	3.68e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PIK3CA—prostate cancer	4.54e-06	3.64e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.51e-06	3.61e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—VEGFA—prostate cancer	4.47e-06	3.58e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—COMT—prostate cancer	4.46e-06	3.58e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTP1—prostate cancer	4.44e-06	3.56e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—AKT1—prostate cancer	4.4e-06	3.53e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ITPR1—prostate cancer	4.37e-06	3.5e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.3e-06	3.44e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—AKT1—prostate cancer	4.22e-06	3.38e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—TYMS—prostate cancer	4.13e-06	3.31e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—TGFB1—prostate cancer	4.1e-06	3.29e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTM1—prostate cancer	4.08e-06	3.27e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—LPL—prostate cancer	4.01e-06	3.21e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP1A1—prostate cancer	3.87e-06	3.1e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ERCC2—prostate cancer	3.84e-06	3.08e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—KRAS—prostate cancer	3.8e-06	3.05e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—AKT1—prostate cancer	3.71e-06	2.97e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—MTHFR—prostate cancer	3.61e-06	2.89e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PPARA—prostate cancer	3.54e-06	2.84e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PIK3CA—prostate cancer	3.49e-06	2.8e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—TP53—prostate cancer	3.38e-06	2.71e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CAV1—prostate cancer	3.33e-06	2.67e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.18e-06	2.55e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PIK3CG—prostate cancer	3.03e-06	2.43e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—INS—prostate cancer	2.87e-06	2.3e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—AKT1—prostate cancer	2.85e-06	2.29e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CREBBP—prostate cancer	2.81e-06	2.25e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PIK3CD—prostate cancer	2.66e-06	2.14e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NOS3—prostate cancer	2.52e-06	2.02e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PIK3CB—prostate cancer	2.32e-06	1.86e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PTGS2—prostate cancer	2.3e-06	1.84e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PTEN—prostate cancer	2.01e-06	1.61e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—EP300—prostate cancer	1.91e-06	1.53e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PIK3CA—prostate cancer	1.42e-06	1.13e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—AKT1—prostate cancer	1.16e-06	9.27e-06	CbGpPWpGaD
